06:01 PM EDT, 10/15/2024 (MT Newswires) -- Aspira Women's Health (AWH) said late Tuesday that the New York State Department of Health's Clinical Laboratory Evaluation Program has approved OvaWatch, its non-invasive blood test for ovarian cancer risk assessment.

The company said the approval allows OvaWatch to be marketed in New York state.

Shares of the company were up 2% in after-hours activity.

Price: 0.8000, Change: +0.02, Percent Change: +2.04